Efficacy and safety of salvage radiotherapy for recurrent esophageal cancer after chemoradiotherapy: a Meta-analysis
10.3760/cma.j.cn113030-20200619-00312
- VernacularTitle:食管癌放化疗后复发再程放疗的 Meta分析
- Author:
Wenhui YU
1
;
Ping ZHANG
;
Chanjun ZHEN
;
Wenwen BAI
;
Sihan LIU
;
Mingyue CHEN
;
Zhiguo ZHOU
Author Information
1. 河北医科大学第四医院/河北省肿瘤医院放疗科，石家庄 050011
- Keywords:
Neoplasm recurrence, esophageal/chemoradiotherapy;
Neoplasm recurrence, esophageal/salvage esophagectomy;
Neoplasm recurrence, esophageal/salvage radiot
- From:
Chinese Journal of Radiation Oncology
2021;30(9):892-897
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the efficacy and adverse events of salvage radiotherapy and other treatments for recurrent esophageal cancer after chemoradiotherapy in this Meta-analysis.Methods:Databases including PubMed, Embase, Cochrane Library, CNKI and Wanfang data were searched from the inception to April 2020 to collect the clinical trials which comparatively analyzed the efficacy and safety between radiotherapy and other treatments for recurrent esophageal cancer after chemoradiotherapy. Meta-analysis was performed using RevMan 5.1 software. RR and 95% CI were used to describe the differences among different groups. Results:According to the inclusion and exclusion criteria, a total of 11 clinical trials involving 842 patients were included. Meta-analysis showed that the overall survival in the salvage radiotherapy group was significantly lower than that in the salvage esophagectomy group ( RR=0.40, 95% CI: 0.27-0.61, P<0.001), whereas significantly higher than that in the chemotherapy group ( RR=2.91, 95% CI: 1.43-5.95, P=0.003). There was no significant difference in the treatment-related mortality between the salvage radiotherapy and salvage esophagectomy groups ( RR=0.53, 95% CI: 0.14-1.98, P=0.350), but the incidence was significantly higher in the salvage esophagectomy group (1.7%-11.4% vs. 1.9%-2.8%). Conclusion:Salvage radiotherapy is an effective treatment for recurrent esophageal cancer after chemoradiotherapy, which can be regarded as one choice for clinical patients.
